Sanofi, Dupixent

Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in sales from its asthma therapy Dupixent.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks Consensus Estimate of $1.35 per share. Earnings of €2.86 per share rose 12.2% on a reported basis and 17.
Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.Most Read from BloombergRobotaxis Are No Friend of Public TransportationBooming Cambridge Exposes England’s Widening Wealth GapOman Sees an Urban Future Distinct From Dubai and Abu DhabiArgentina Drug Trafficking Hotspot Sees Murders PlungeClimate Change Is Killing Buildings in Slow MotionEarnings per share excluding some items reached €2.
Sanofi Profit, Sales Beat Estimates
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.
Managed Healthcare Executive6d
Long-Term Dupixent Treatment Shows Promising Results for Severe Atopic Dermatitis
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Pharmabiz2d
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...
BioSpace13d
Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...
Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...
Morningstar6d
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.
Finanznachrichten3d
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if ...
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...
Eli Lilly's Ebglyss Emerges as New Option for Patients Struggling with Dupixent Treatment
Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...
Sanofi: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...